Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treatment of hypercalcemia.

M F Attie1

  • 1University of Pennsylvania School of Medicine, Philadelphia.

Endocrinology and Metabolism Clinics of North America
|September 1, 1989
PubMed
Summary
This summary is machine-generated.

Severe hypercalcemia, often caused by cancer, requires prompt treatment including fluid expansion and bone resorption inhibitors like bisphosphonates. Early intervention with these therapies can normalize calcium levels within days.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of testosterone treatment on bone mineral density in men over 65 years of age.

The Journal of clinical endocrinology and metabolism·1999
Same author

Osteoporosis and bone morbidity in cardiac transplant recipients.

The American journal of medicine·1994
Same author

A longitudinal study of metacarpal bone morphometry in anorexia nervosa.

Clinical orthopaedics and related research·1992
Same author

Bisphosphonate therapy for osteoporosis.

Hospital practice (Office ed.)·1991
Same author

Management of severe hypercalcemia.

Critical care clinics·1991
Same author

WR-2721 reduces bone loss after hindlimb tenotomy in rats.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·1989

Area of Science:

  • Endocrinology
  • Oncology
  • Nephrology

Background:

  • Severe hypercalcemia is a life-threatening condition frequently linked to cancers that increase bone resorption.
  • Impaired renal calcium excretion, due to volume contraction and nephrocalcinosis, exacerbates hypercalcemia.
  • Understanding the pathophysiology is crucial for effective management.

Purpose of the Study:

  • To outline the critical role of impaired renal calcium excretion in hypercalcemia.
  • To review current treatment strategies for severe hypercalcemia.
  • To discuss the efficacy and timing of various hypocalcemic agents.

Main Methods:

  • Review of established treatments for hypercalcemia.
  • Analysis of agents that reduce bone resorption, including bisphosphonates and plicamycin (mithramycin).

Related Experiment Videos

  • Evaluation of supportive measures like fluid expansion and electrolyte correction.

    • Main Results:

    • Bisphosphonates and plicamycin, combined with volume expansion, effectively normalize serum calcium in 3-6 days.
    • Calcitonin offers rapid but modest calcium reduction; combination therapy enhances efficacy.
    • Non-pharmacological methods like ambulation and avoiding sedatives are also important.

    Conclusions:

    • Prompt administration of hypocalcemic agents is vital due to their delayed action.
    • Integrated treatment addressing the underlying disease and supportive care is essential.
    • Future research may enable prediction and prophylactic treatment of hypercalcemia in at-risk cancer patients.